Akums Drugs and Pharmaceuticals IPO Allotment Status Online: Akums Drugs and Pharmaceuticals IPO is Open on 26 July, 2024 and Close on 30 July, 2024. Akums Drugs and Pharmaceuticals IPO to Raise 27,345,162 shares (Appprox ₹1,856.74 Cr) via IPO. The Fresh Issue of 10,014,727 shares (Approx ₹680.00 Cr) and The Offer For Sale is 17,330,435 shares of ₹2 (Approx ₹1,262.83 Cr).
- The Retail Quota is 35%
- QIB is 50%
- NII is 15%
Akums Drugs and Pharmaceuticals IPO Basis of Allotment Status on 2 August 2024. Akums Drugs and Pharmaceuticals IPO Refund Date is 5 August 2024 and Akums Drugs and Pharmaceuticals IPO Credit to Demat on 5 August 2024.
Also Read: Akums Drugs and Pharmaceuticals IPO Details Today, GMP Price, Date, Review
Akums Drugs and Pharmaceuticals IPO Allotment Link Online
Linktime
Linktime Allotment Link
Moneymintidea
IPO Allotment Status Link
About –
Akums Drugs and Pharmaceuticals Established in 2004, we are a pharmaceutical contract development and manufacturing organization (“CDMO”) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the leading CDMOs in India, we own the intellectual property for the manufacturing processes of several of our formulations, and our core business is focused on providing end-to-end product development and manufacturing solutions to our clients.
Some of our other services include formulation research and development (“R&D”), preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. In addition to our core CDMO business. we are also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (“APIs”) .
We produce an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies, among others. we have manufactured 4,025 commercialised formulations across over 60 dosage forms.
key clients for our CDMO business include Alembic Pharmaceuticals, Alkem Laboratories, Blue Cross Laboratories, Cipla, Dabur India, Dr. Reddy’s Laboratories, Hetero Healthcare, Ipca Laboratories, Mankind Pharma, MedPlus Health Services, Micro Labs, Mylan Pharmaceuticals, Natco Pharma, Sun Pharmaceutical Industries, UCB, and Amishi Consumer Technologies (The Mom’s Co), among others.
Our international presence extends across 60 countries, and our key clients include Allegens (Vietnam), Ambica International (Philippines), Caferma SAC (Peru), JDS (Myanmar), Master Pharma (Cambodia), Olainfarm (Latvia), Pharma Apex (Myanmar), Planet Pharmaceutical (Tanzania), and Unisel (Kenya), among others.
